Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.

Bonifacius A, Tischer-Zimmermann S, Santamorena MM, Mausberg P, Schenk J, Koch S, Barnstorf-Brandes J, Gödecke N, Martens J, Goudeva L, Verboom M, Wittig J, Maecker-Kolhoff B, Baurmann H, Clark C, Brauns O, Simon M, Lang P, Cornely OA, Hallek M, Blasczyk R, Seiferling D, Köhler P, Eiz-Vesper B

Open source

DOI: 10.3389/fbioe.2022.867042
Published: 2022
Container: Frontiers in bioengineering and biotechnology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fbioe.2022.867042,
  title = {Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.},
  author = {Bonifacius A and Tischer-Zimmermann S and Santamorena MM and Mausberg P and Schenk J and Koch S and Barnstorf-Brandes J and Gödecke N and Martens J and Goudeva L and Verboom M and Wittig J and Maecker-Kolhoff B and Baurmann H and Clark C and Brauns O and Simon M and Lang P and Cornely OA and Hallek M and Blasczyk R and Seiferling D and Köhler P and Eiz-Vesper B},
  year = {2022},
  journal = {Frontiers in bioengineering and biotechnology},
  doi = {10.3389/fbioe.2022.867042},
  url = {https://doi.org/10.3389/fbioe.2022.867042}
}

RIS

TY  - JOUR
TI  - Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.
AU  - Bonifacius A
AU  - Tischer-Zimmermann S
AU  - Santamorena MM
AU  - Mausberg P
AU  - Schenk J
AU  - Koch S
AU  - Barnstorf-Brandes J
AU  - Gödecke N
AU  - Martens J
AU  - Goudeva L
AU  - Verboom M
AU  - Wittig J
AU  - Maecker-Kolhoff B
AU  - Baurmann H
AU  - Clark C
AU  - Brauns O
AU  - Simon M
AU  - Lang P
AU  - Cornely OA
AU  - Hallek M
AU  - Blasczyk R
AU  - Seiferling D
AU  - Köhler P
AU  - Eiz-Vesper B
PY  - 2022
JO  - Frontiers in bioengineering and biotechnology
DO  - 10.3389/fbioe.2022.867042
UR  - https://doi.org/10.3389/fbioe.2022.867042
ER  -

APA

A, B., S, T., MM, S., P, M., J, S., S, K., J, B., N, G., J, M., L, G., M, V., J, W., B, M., H, B., C, C., O, B., M, S., P, L., OA, C., M, H., R, B., D, S., P, K., & B, E. (2022). Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.. Frontiers in bioengineering and biotechnology. https://doi.org/10.3389/fbioe.2022.867042

Source records

pubmed · retrieved 2026-09-27T10:59:35.983Z
europe-pmc · retrieved 2026-09-27T10:59:35.991Z
doaj · retrieved 2026-09-27T10:59:36.002Z